Disclosures. 2 Study ARQ197-A-U252; Presented by C. Eng, MD
|
|
- Susan Lamb
- 5 years ago
- Views:
Transcription
1 Abstract: 358 A Randomized, Placebo-Controlled, Phase 2 Study of Tivantinib (ARQ 197) in Combination With Cetuximab and Irinotecan as Second-Line Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Cathy Eng, 1 Lowell L. Hart, 2 Aleksey Severtsev, 3 Oleg Gladkov, 4 Lothar Muller, 5 Mikhail V. Kopp, 6 Vladimir Vladimirov, 7 Robert Langdon, 8 Bogdan Kotiv, 9 Sandro Barni, 1 Ching Hsu, 11 Ellen Bolotin, 11 Reinhard von Roemeling, 11 Brian Schwartz, 12 Johanna C. Bendell 13 1 The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2 Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL; 3 The Central Clinical Hospital #1, Moscow, Russia; 4 Chelyabinsk Regional Clinical Oncological Dispensary, Chelyabinsk, Russia; 5 Onkologische Schwerpunktpraxis Leer-Emden, Leer, Germany; 6 Samara Regional Clinical Oncology Dispensary, Samara, Russia; 7 Pyatigorsk Oncological Dispensary, Pyatigorsk, Russia; 8 Nebraska Methodist Hospital Cancer Center, Omaha, NE; 9 Military Medical Academy, St. Petersburg, Russia; 1 Azienda Ospedaliera di Treviglio Ospedale, Treviglio, Italy; 11 Daiichi Sankyo, Inc., Edison, NJ; 12 ArQule, Inc., Woburn, MA; 13 Sarah Cannon Research Institute, Nashville, TN
2 Disclosures The trial was funded by Daiichi Sankyo, Inc., a member of the Daiichi Sankyo Group, and ArQule, Inc. I have received research funding from Daiichi Sankyo for this trial 2
3 CRC Background Colorectal cancer (CRC) is the fourth most common cancer and second leading cause of cancer death in the US (for men and women combined) 1 Approximately 4% of patients develop metastatic disease 2 Current standard treatments are administered in combination or as single agents and include 3 Chemotherapy (fluoropyrimidines, oxaliplatin, irinotecan/cpt-11) Monoclonal antibodies (bevacizumab, cetuximab, panitumumab) Small molecules (regorafenib) 1. American Cancer Society Cancer. Colorectal Cancer Facts and Figures Fedorowicz Z, et al. Cochrane Database Syst Rev. 28;(2):CD639. DOI: 1.12/ CD639.pub4. 3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V
4 MET in CRC MET overexpression may occur in 3% to 7% of CRC tumors, and is associated with poor prognosis and resistance to radiation 1 MET plays an important role in CRC progression and metastasis 2 Resistance to cetuximab has been associated with activation of alternative RTK pathways, including MET 3 We hypothesized that adding tivantinib to cetuximab plus irinotecan may decrease resistance to cetuximab and improve patient outcomes 1. Takeuchi H, et al. Clin Cancer Res. 23;9(4): Zeng ZS, et al. Cancer Lett. 28;265(2): Walther A, et al. Nat Rev Cancer. 29;9(7):
5 Tivantinib (ARQ 197) A selective oral MET inhibitor with a novel ATP-independent binding mechanism 1 Broad-spectrum antitumor activity as single-agent and combination therapy demonstrated in preclinical studies, including MET-high CRC cell lines 2,3 Promising phase 1b data in CRC showed safety of the combination at full dose and included 4 objective responses in 9 patients 4 Reprinted from Eathiraj et al. 1. Eathiraj S, et al. J Biol Chem. 211;286(23): Munshi N, et al. Mol Cancer Ther. 21;9(6): Lu S, et al. Z Gastroenterol. 212;5:P5_31. DOI: 1.155/s Eng C, et al. Ann Oncol. 212;23(suppl 4). Abstract PD-18. 5
6 Phase 2 Study Design Eligibility Age 18 years Inoperable, locally advanced or metastatic disease KRAS WT 1 line of prior systemic Tx ECOG -1 No prior anti-egfr therapy Stratification Factors: 1) ECOG ( vs 1) 2) Best response to 1st-line therapy (CR/PR/SD vs PD) R A N D O M I Z E D O U B L E B L I N D N = 15 1:1 Tivantinib (ARQ 197) 36 mg PO BID Placebo PO BID + + Primary Endpoint: PFS Secondary Endpoints: OS, ORR, safety Cetuximab 5 mg/m 2 IV q14 days Irinotecan 18 mg/m 2 IV q14 days Cetuximab 5 mg/m 2 IV q14 days Irinotecan 18 mg/m 2 IV q14 days 6
7 Accrual and Statistics Accrual: Jul 21 to Feb 212 in US, Russia, France, Italy, Germany Total Patients Randomized 122 Full Analysis Set: pts with postbaseline scan eligible for efficacy analysis 117 Safety Data Set: pts who received study drug 121 Recruitment was discontinued early before the pre-specified goal of 15 was reached. The number of PFS events for analysis was decreased from 11 to 8, which provides 7% power to detect a 5% improvement in median PFS at P =.1 (1-sided) 7
8 Patient Disposition Tivantinib Placebo Randomized, n 62 6 Full analysis set, n 6 57 Treatment discontinuation, n (%) 53 (85.5) 47 (78.3) Progressive disease 34 (54.8) 28 (46.7) Adverse event 12 (19.4) 6 (1.) Patient withdrew consent 1 (1.6) 3 (5.) Lost to follow-up 1 (1.6) Death 1 (1.7) Other a 5 (8.1) 9 (15.) Treatment ongoing, n (%) 9 (14.5) 13 (21.7) a Other includes clinical progression, investigator discretion, patient decision, patient relocation. 8
9 Patient Demographics Full Analysis Set Mean age, y (min - max) SD Tivantinib (n = 6) Placebo (n = 57) (29-79) (27-79) Gender, n (%) Male 26 (43.3) 32 (56.1) Female 34 (56.7) 25 (43.9) Race, n (%) Caucasian 57 (95.) 54 (94.7) Black 2 (3.3) 1 (1.8) Asian 1 (1.7) 2 (3.5) ECOG score, n (%) 36 (6.) 28 (49.1) 1 24 (4.) 29 (5.9) 9
10 Patient Characteristics Full Analysis Set Tivantinib (n = 6) Placebo (n = 57) Prior radiation, n (%) 9 (15.) 1 (17.5) Prior surgery, n (%) 53 (88.3) 48 (84.2) Time from diagnosis to treatment, d SD Prior systemic cancer therapy, n (%) Fluoropyrimidine 6 (1) 55 (97) Oxaliplatin 47 (78) 48 (84) Bevacizumab 33 (55) 25 (44) Irinotecan 1 (17) 11 (19) Other 6 (1) 8 (14) Best response to prior therapy, n (%) CR, PR, SD 44 (73.3) 35 (61.4) PD 16 (26.7) 22 (38.6) 1
11 Progression-Free Survival, % Progression-Free Survival Full Analysis Set (median follow-up: 15.9 mo) 1 75 HR =.85 (95% CI, ) Stratified log-rank P =.38 Events Median, mo 95% CI T P Tivantinib (n = 6) Placebo (n = 57) Time Since Randomization, mo 11
12 Overall Survival, % Overall Survival Full Analysis Set (median follow-up: 21.5 mo) 1 75 HR =.7 (95% CI, ) Stratified log-rank P =.25 Events Median, mo 95% CI T P Tivantinib (n = 6) Placebo (n = 57) Time Since Randomization, mo 12
13 Best Overall Response Full Analysis Set Best Response, n (%) Tivantinib (n = 6) Placebo (n = 57) Complete response Partial response 27 (45.) 19 (33.3) Stable disease 22 (36.7) 22 (38.6) Progressive disease 9 (15.) 13 (22.8) Not evaluable 2 (3.3) 3 (5.3) Objective response rate (CR + PR) [95% CI] Stable disease or better [95% CI] 27 (45.) [ ] 49 (81.7) [ ] 19 (33.3) [ ] 41 (71.9) [ ] 13
14 Change From Baseline, % Tumor Response Investigator Assessed Tivantinib Placebo 14
15 Adverse Events (> 15% Frequency) Safety Population Tivantinib (n = 62) Placebo (n = 59) Preferred Term, n (%) All Grades Grade 3 All Grades Grade 3 Rash 36 (58) 5 (8) 34 (58) 5 (9) Diarrhea 33 (53) 8 (13) 3 (51) 5 (9) Nausea 27 (44) 6 (1) 27 (46) 4 (7) Fatigue 24 (39) 3 (5) 2 (34) 2 (3) Vomiting 2 (32) 3 (5) 18 (31) 3 (5) Neutropenia 18 (29) 12 (19) 12 (2) 6 (1) Abdominal pain 12 (19) 15 (25) 4 (7) Decreased appetite 11 (18) 1 (2) 7 (12) 1 (2) Dry skin 11 (18) 1 (17) Constipation 1 (16) 11 (19) Dermatitis acneform 8 (13) 1 (1) 9 (15) 1 (2) Anemia 7 (11) 18 (31) 1 (2) 15
16 Outcomes in Key Subgroups Group Tivantinib, n (%) Placebo, n (%) PFS HR (95% CI) a OS HR (95% CI) a All ( ).68 ( ) Male 26 (43) 32 (56) 1.28 ( ) 1.9 ( ) Female 34 (57) 25 (44).52 ( ).45 ( ) ECOG 36 (6) 28 (49) 1.1 (.6-2.1).75 ( ) ECOG 1 24 (4) 29 (51).69 ( ).63 ( ) Age 65 y 45 (75) 41 (72).81 ( ).6 ( ) Age > 65 y 15 (25) 16 (28).88 ( ).99 ( ) Prior systemic therapy Oxaliplatin 47 (78) 48 (84).66 ( ).58 ( ) Fluoropyrimidine 6 (1) 55 (96).8 ( ).66 (.4-1.1) Irinotecan 1 (17) 11 (19) 3.36 ( ) 1. (.3-3.3) Bevacizumab 33 (55) 25 (44).61 ( ).73 ( ) a HR/OR < 1. favors tivantinib; HR/OR > 1. favors placebo. 16
17 Progression-Free Survival, % Overall Survival, % Outcomes in Patients Treated With Prior Oxaliplatin PFS HR =.66 (95% CI, ) Stratified log-rank P =.1 Median 95% CI T 8.3 mo P 7.2 mo OS HR =.58 (95% CI, ) Stratified log-rank P =.6 Median 95% CI T 22.3 mo P 14.1 mo Tivantinib (n = 47; 33 events) Placebo (n = 48; 33 events). Tivantinib (23 events) Placebo (28 events) Time Since Randomization, mo Time Since Randomization, mo Tivantinib Placebo ORR 42.6% 27.1% 17
18 Biomarkers MET IHC Available archival tissue tested centrally for total MET expression using the anti-met (SP44) antibody (Spring Biosciences) High: 5% of tumor cells with immunostaining intensity of 2 + or 3 + N = 67 (59 primary tumors; 8 metastatic lesions) HGF serum concentration High: > mean baseline concentration for the subgroup Low: mean baseline concentration 18
19 Overall Survival, % Overall Survival, % Progression-Free Survival, % Progression-Free Survival, % PFS and OS by MET Expression 1 75 PFS MET-High MET-Low ORR: T = 54.2%; P = 3.% ORR: T = 27.3%; P = 41.7% HR =.74 (95% CI, ) Log-rank P = HR =.22 (95% CI,.6 -.8) Log-rank P = Tivantinib (n = 24) Placebo (n = 2) OS 21 HR =.58 (95% CI, ) Log-rank P = Tivantinib (n = 11) Placebo (n = 12) HR =.78 (95% CI, ) Log-rank P = Time Since Randomization, mo Time Since Randomization, mo 19
20 Overall Survival, % Overall Survival, % Progression-Free Survival, % Progression-Free Survival, % PFS and OS by Serum HGF Level 1 PFS HGF-High HGF-Low ORR: T = 44.8%; P = 25.% ORR: T = 46.7%; P = 39.3% 1 75 HR =.7 (95% CI, ) Log-rank P = HR =.94 (95% CI,.5-1.8) Log-rank P = OS Tivantinib (n = 29) Placebo (n = 28) HR =.61 (95% CI, ) Log-rank P = Tivantinib (n = 3) Placebo (n = 28) HR =.7 (95% CI, ) Log-rank P = Time Since Randomization, mo Time Since Randomization, mo 2
21 Overall survival, % Overall Survival by Baseline Serum HGF Level in Placebo Patients 1 8 High (n = 28) Low (n = 28) HR = 2.14 (95% CI: 1.1, 4.53) Events Median, mo 95% CI High , 19.2 Low , Time Since Randomization, mo 21
22 Conclusions Tivantinib in combination with cetuximab and irinotecan had a similar safety profile to cetuximab and irinotecan alone, except for a higher incidence of neutropenia PFS, ORR, and OS all trended in favor of tivantinib, particularly among patients who received prior oxaliplatin Efficacy signals in the small MET-high (by IHC) subgroup were inconclusive; require further validation with a larger sample size HGF concentration is a prognostic indicator of OS and warrants further analysis While results are encouraging, they highlight the need for uniform tissue and blood collection prior to enrollment to allow more robust correlative outcome assessments in the MET pathway 22
23 Next Steps for Tivantinib These encouraging findings will be informed by additional data from ongoing studies: Phase 2 study of tivantinib in combination with cetuximab in patients who failed cetuximab, currently enrolling in Italy Phase 1 study of tivantinib in combination with FOLFOX in the US (ASCO 213, abstract 2544) Phase 3 study of tivantinib vs placebo in MET-high HCC (2 nd -line) (ASCO 213, poster TPS4519) Additional work is needed to better characterize changes in MET expression from diagnosis through treatment and following progression of disease, particularly in oxaliplatin-pretreated patients Prior studies suggest that MET overexpression is a late event, thus MET analysis as predictive biomarker may be best obtained from metastatic lesions Based on these results the most promising path forward will be determined 23
24 Acknowledgments We thank the patients and their families and all the investigators Principle investigators Francis Arena, Lake Success, NY, USA Alberto Bessudo, San Diego, CA, USA Corrado Boni, Reggio Emilia, Italy Roger Brito, Boynton Beach, FL, USA Brian Choi, Riverside, CA, USA Christophe Desauw, Lille, France Irfan Firdaus, Cincinnati, OH, USA Nashat Gabrail, Canton, OH, USA George Geils, Jr., Charleston, SC, USA Philip Gold, Seattle, WA, USA Jayne Gurtler, Metairie, LA, USA James Hays, Centralia, IL, USA David Hoffman, Beverly Hills, CA, USA Ralf-Dieter Hofheinz, Mannheim, Germany Haresh Jhangiani, Fountain Valley, CA, US Dinesh Kapur, Norwich, CT, USA Omar Kayaleh, Orlando, FL, USA Igor Kiselev, Kursk, Russia Fred Kudrik, Columbia, SC, USA Pallavi Kumar, Baltimore, MD, USA Wen Wee Ma, Buffalo, NY, USA Robert Marschke, Fort Collins, CO, USA Michael McCormack, Hagerstown, MD, USA Shubham Pant, Oklahoma City, OK, USA Hervé Perrier, Marseille, France Maciej Rotarski, Bayonne, France Armando Santoro, Rozzano, Milan, Italy Hans-Joachim Schmoll, Halle (Saale), Germany Jens Siveke, Munchen, Germany DMC members: John Lindsay Marshall, Jean Grem, Mithat Gonen, Vanessa Beddo ArQule, Inc: Yinpu Chen, Julia Kazakin, Matt McLeod Daiichi Sankyo: Abdel-Baset Halim, Taina Lopez, Dale Shuster, Koichi Tazaki, Hamim Zahir Editorial support provided by Accuverus This study was sponsored by Daiichi Sankyo, Inc., a member of the Daiichi Sankyo Group, and ArQule, Inc. 24
Randomized Controlled Phase 2 Trial (RCT) ARQ
Tivantinib in Pretreated Hepatocellular Carcinoma (HCC): Tumor and Plasma Biomarker Analysis from the Randomized Controlled Phase 2 Trial (RCT) ARQ 197-215 L Rimassa, G Abbadessa, N Personeni, C Porta,
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationSecond Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) C Porta, I Borbath, L Rimassa, B Daniele, S Salvagni, JL Van Laethem, H Van
More informationRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) ASCO Annual Meeting 2017 Randomized trial of irinotecan and cetuximab with
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationTivantinib Overview April 2016
Tivantinib Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationA Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma Patrick A. Ott, MD, PhD 1, Anna C. Pavlick, DO 2, Douglas B. Johnson, MD 3, Lowell Hart, MD 4,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015
Supported by an Independent Educa1onal Grant from MEETING SUMMARY ASCO GI, SATURDAY JANUARY 17 TH 2015 BY DR. GUILLEM ARGILES, BARCELONA, SPAIN Cancers of the Lower GI Tract RAISE: A RANDOMIZED, DOUBLE-BLIND,
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationKRAS G13D mutation testing and anti-egfr therapy
KRAS G13D mutation testing and anti-egfr therapy KRAS G13D mutation and anti-egfr therapy Current data do not support a need to specifically identify this mutation for assessing anti-egfr eligibility in
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationJefferies 2014 Global Healthcare Conference. June 5, 2014
Jefferies 2014 Global Healthcare Conference June 5, 2014 ArQule, Inc. Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationClinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationINDICATION: COMPENDIA TRANSPARENCY TRACKING FORM
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Panitumumab INDICATION: Metastatic colorectal cancer, wild-type KRAS mutation, first-line therapy, in combination with infusional fluorouracil, leucovorin, and
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationColon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome
Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationINITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR INHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS. S George, M Heinrich, P
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More information